The fireside chat is scheduled for Monday, September 14, at 3:30 PM ET. Investors and stakeholders can access a live webcast of the presentation through the Investor Relations section of the company's website, with a replay available shortly after the session concludes. Those looking to coordinate private meetings are advised to contact their H.C. Wainwright representatives directly.
In section Releases
Compugen Management Heads to H.C. Wainwright Global Investment Conference
Compugen leadership is set to engage with investors at the H.C. Wainwright 28th Annual Global Investment Conference in New York City. Running from September 14-16, 2026, the event will feature a fireside chat with company management alongside one-on-one sessions to discuss the firm’s clinical-stage immuno-oncology pipeline.
Based in Holon, Israel, Compugen focuses on computational target discovery through its proprietary Unigen AI platform. The company’s current pipeline includes the anti-PVRIG antibody COM701, currently undergoing the MAIA-ovarian clinical trial, as well as the PD-1/TIGIT bispecific antibody rilvegostomig, which is being developed in partnership with AstraZeneca. Additionally, the firm is advancing GS-0321, a high-affinity antibody licensed to Gilead that is now in Phase 1 testing. Compugen remains publicly traded on both Nasdaq and the Tel Aviv Stock Exchange under the ticker CGEN.
Comments (0)
No comments yet. Be the first!